O Glimaday 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The combination of these two agents offers complementary mechanisms of action, providing effective control of blood glucose levels in patients inadequately managed with diet and exercise alone or monotherapy. O Glimaday 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan that includes lifestyle modifications such as diet and exercise. It is essential to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, a potential adverse effect primarily associated with Glimepiride. Metformin’s common side effects include gastrointestinal disturbances, which often diminish with continued use. This medication should be used cautiously in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. O Glimaday 2 Tablet PR is contraindicated in type 1 diabetes and diabetic ketoacidosis. Regular medical supervision is advised to optimize therapeutic outcomes and ensure patient safety.